Статті-сироти

Перейти до: навігація, пошук

На такі сторінки нема посилань з інших сторінок і вони не включаються до інших сторінок HistoryPedia.

Нижче показано до 50 результати у діапазоні від #96 661 до #96 710.

Переглянути (попередні 50 • наступні 50) (20 • 50 • 100 • 250 • 500).

  1. The Controversy Around Questionable Thalidomide-Concepts
  2. The Controversy Around Questionable Vorinostat-Methods
  3. The Controversy Around Risky BIBF 1120-Activities
  4. The Controversy Around Risky PD-0332991-Practices
  5. The Controversy Around Risky R428-Method
  6. The Controversy Around Risky Vemurafenib-Method
  7. The Controversy Around Ruthless AZD9291-Tactics
  8. The Controversy Around Ruthless Azacitidine-Promotions
  9. The Controversy Around Ruthless BLZ945-Practices
  10. The Controversy Around Ruthless CGK 733-Concepts
  11. The Controversy Around Ruthless GDC-0449-Techniques
  12. The Controversy Around Ruthless GRB10-Concepts
  13. The Controversy Around Ruthless JNK inhibitor-Activities
  14. The Controversy Around Ruthless LY2835219-Activities
  15. The Controversy Around Ruthless Obeticholic Acid-Strategies
  16. The Controversy Around Ruthless Pexidartinib-Systems
  17. The Controversy Around Ruthless SCH727965-Methods
  18. The Controversy Around Ruthless Sorafenib-Systems
  19. The Controversy Around Ruthless Y-27632-Methods
  20. The Controversy Over Callous Carboplatin-Procedures
  21. The Controversy Over Callous Dorsomorphin-Promotions
  22. The Controversy Over Callous Epacadostat-Methods
  23. The Controversy Over Callous Imatinib-Systems
  24. The Controversy Over Callous LGK-974-Tactics
  25. The Controversy Over Callous Lenvatinib-Tactics
  26. The Controversy Over Callous NU7441-Promotions
  27. The Controversy Over Callous Quinapyramine-Promotions
  28. The Controversy Over Callous S1PR1-Systems
  29. The Controversy Over Callous S6 Kinase-Strategies
  30. The Controversy Over Callous Sitaxentan-Practices
  31. The Controversy Over Callous TRIB1-Techniques
  32. The Controversy Over Callous Temsirolimus-Tactics
  33. The Controversy Over Callous Vatalanib (PTK787) 2HCl-Practices
  34. The Controversy Over Callous Vemurafenib-Systems
  35. The Controversy Over Callous ZD1839-Systems
  36. The Controversy Over Callous flupentixol-Approaches
  37. The Controversy Over Callous flupentixol-Procedures
  38. The Controversy Over Contentious Everolimus-Activities
  39. The Controversy Over Contentious GS-7340-Procedures
  40. The Controversy Over Contentious INCB018424-Activities
  41. The Controversy Over Controversial Alectinib-Approaches
  42. The Controversy Over Controversial FDA-approved Drug Library-Strategies
  43. The Controversy Over Controversial FXR-Tactics
  44. The Controversy Over Controversial GSK126-Practices
  45. The Controversy Over Controversial PCI-32765-Tactics
  46. The Controversy Over Controversial PD-0332991-Promotions
  47. The Controversy Over Controversial PD0325901-Systems
  48. The Controversy Over Controversial Thalidomide-Promotions
  49. The Controversy Over Questionable Doxorubicin-Practices
  50. The Controversy Over Questionable Doxorubicin-Systems

Переглянути (попередні 50 • наступні 50) (20 • 50 • 100 • 250 • 500).

Отримано з http://istoriya.soippo.edu.ua/index.php?title=Спеціальна:Ізольовані_сторінки